Literature DB >> 9075771

A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation.

R J Szarka1, N Wang, L Gordon, P N Nation, R H Smith.   

Abstract

This study examines the intranasal instillation of lipopolysaccharide (LPS) into BALB/c mice causing acute pulmonary damage, due to neutrophil infiltration and sepsis. A dose response with LPS showed that an intranasal instillation of 167 microg/ml (10 microg/mouse) caused acute lung injury within 2-4 h and reached maximal damage at 24-48 h. We found the method of LPS administration for induction of acute pulmonary damage to be crucial. After 24 h post-LPS injection, a comparison showed a substantial increase in pulmonary damage with intranasal instillation of LPS. As for intravenous injection, it showed a baseline effect. This study indicates that LPS administered intranasally causes acute pulmonary damage, whereas with intravenous and intraperitoneal endotoxin administration a tissue-specific or similar degree of pulmonary injury may not develop.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075771     DOI: 10.1016/s0022-1759(96)00236-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  76 in total

1.  Effect of low doses of lipopolysaccharide prior to ozone exposure on bronchoalveolar lavage: Differences between wild type and surfactant protein A-deficient mice.

Authors:  Rizwanul Haque; Todd M Umstead; Kwangmi Ahn; David S Phelps; Joanna Floros
Journal:  Pneumon       Date:  2009

2.  Short-term cigarette smoke exposure predisposes the lung to secondary injury.

Authors:  Tapan M Bhavsar; Joseph M Cerreta; Jerome O Cantor
Journal:  Lung       Date:  2007-06-13       Impact factor: 2.584

3.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment.

Authors:  Jordanna G Jayne; Timothy J Bensman; Justin B Schaal; A Young J Park; Elza Kimura; Dat Tran; Michael E Selsted; Paul M Beringer
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

5.  Effect of dobutamine on lung aquaporin 5 in endotoxine shock-induced acute lung injury rabbit.

Authors:  Cai-Zhi Sun; Hua Shen; Xiao-Wei He; Lei Bao; Yang Song; Zheng Zhang; Hai-Dong Qin
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

6.  Propofol attenuates pulmonary injury induced by collapse and reventilation of lung in rabbits.

Authors:  Hong-Beom Bae; Mei Li; Seong-Heon Lee; Cheol-Won Jeong; Seok-Jai Kim; Heong-Seok Kim; Sung-Su Chung; Sang-Hyun Kwak
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

7.  Angiostatin inhibits acute lung injury in a mouse model.

Authors:  Gurpreet K Aulakh; Sarabjeet S Suri; Baljit Singh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

8.  Acrolein inhalation suppresses lipopolysaccharide-induced inflammatory cytokine production but does not affect acute airways neutrophilia.

Authors:  David Itiro Kasahara; Matthew E Poynter; Ziryan Othman; David Hemenway; Albert van der Vliet
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  The effect of epigallocatechin gallate on lipopolysaccharide-induced acute lung injury in a murine model.

Authors:  Hong-Beom Bae; Mei Li; Jong-Phil Kim; Seok-Jai Kim; Cheol-Won Jeong; Hyung-Gon Lee; Woong-Mo Kim; Hyung-Seok Kim; Sang-Hyun Kwak
Journal:  Inflammation       Date:  2010-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.